Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.1% (Ikervis) for Meibomian Gland Dysfunction in Dry Eye Disease
KCT0010369Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of cyclosporine in dry eye syndrome (DED), meibomian gland dysfunction (MGD), sponsored by Santen Pharmaceutical. Started Apr 2022; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on KCT0010369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010369.